School Of Medicine
Dr. Ralf Huss joined Definiens in 2013 and has more than 20 years of training and experience in histopathology and cancer research.
Prior to joining Definiens, Dr. Huss served as Global Head of Histopathology and Tissue Biomarkers at Roche Diagnostics, where he was involved in identifying new tissue biomarkers to stratify cancer patients as part of a global Personalized Healthcare strategy. Dr. Huss also co-founded the biotech company APCETH. He has training and experience in immunology, transplantation biology and stem cell research, has published more than 100 papers, and has worked with the Nobel Laureates Rolf Zinkernagel and E. Donnell Thomas.
In his role as Chief Medical Officer, Dr. Huss plays a key role in expanding Definiens¿ image and data analysis into Tissue Diagnostics and Clinical Digital Pathology.
Dr. Huss holds global academic appointments at the Ludwig-Maximilians-University, Munich and the Wake Forest Institute for Regenerative Medicine, USA. He is also a Professor of Systems Biology at the University College Dublin
Peer Reviewed Journals
|Huss R, Renner-M¿¿ller I;Buchstaller A (2005) 'Adult scl+/+ murine hemangioblasts persist in allogeneic mutant blastocysts but fail to rescue the scl-/- phenotype'. Stem Cells and Development, 14 (4):402-407. [DOI] [Details]|
|Wegmeyer H, Br¿¿ske AM;Leddin M;Kuentzer K;Nisslbeck AK;Hupfeld J;Wiechmann K;Kuhlen J;von Schwerin C;Stein C;Knothe S;Funk J;Huss R;Neubauer M (2013) 'Mesenchymal stromal cell characteristics vary depending on their origin'. Stem Cells and Development, 22 (19):2606-2618. [DOI] [Details]|
|Hupfeld J, Gorr IH;Schwald C;Beaucamp N;Wiechmann K;Kuentzer K;Huss R;Rieger B;Neubauer M;Wegmeyer H (2014) 'Modulation of mesenchymal stromal cell characteristics by microcarrier culture in bioreactors'. Biotechnology and Bioengineering, 111 (11):2290-2302. [DOI] [Details]|